 Single-agent gemcitabine is currently still regarded as one international standard of care for patients with advanced pancreatic cancer Burris 1997 4. The oral EGFR tyrosine kinase inhibitor erlotinib received EMEA-approval for the treatment of patients with metastatic pancreatic cancer in January 2007. 